DURHAM – Target RWE is adding to the company’s executive team, hiring Derek Evans as president.

The company announced the news today in a statement.

“In this new role, Derek will lead all operating functions as we continue to leverage our significant software, data, and intellectual assets and capabilities for our partners,” said Neal Bibeau, CEO of Target RWE.

The company, which acquired the Durham-based software analytics company NoviSci, Inc., in January 2021, combined the two startups with financial backing in the form of a strategic investment from Amgen.  Amgen announced earlier this year that it will build a facility in Holly Springs, and hire as many as 355 employees into high-paying roles.

Biotech giant Amgen invests after Durham startups combine in healthcare data deal

The company “designs custom datasets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives,” according to its website.  The company can then offer to its clients a “turnkey health evidence solution which rapidly aggregates real-world data,” it states on its website.

The company is hiring for other roles, as well, as the careers website lists seven openings in Durham.

“Target RWE has gained significant momentum toward delivering on the promise of real-world evidence to the healthcare industry, providers, and most importantly, to the patients who live with often chronic and co-morbid conditions,” said Derek Evans in a statement.

Life science firm Amgen picks Holly Springs for plant, hundreds of jobs at $120,000 pay

Evans most recently was the general manager of decision analytics and innovation at Change Healthcare, a provider of a healthcare analytics platform.

“I am excited to join the organization at this critical time to accelerate the great work that is currently underway,” said Evans in the statement.  “Target RWE is poised at the precipice of healthcare innovation by bringing together unique real world data, novel analytics, and cutting-edge technology at scale to improve healthcare outcomes. With our proprietary technology, we can aid our clients in making better decisions which speed time to market, reduce investment and improve patient outcomes.”

Earlier this year, the company announced the addition of Dr. Andrew von Eschenbach as a senior advisor, the company statement noted.